Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of hospital acquired pneumonia are common in immunocompromised patients, post surgical infections, enteral feeding, elderly and infant patients. As hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator air, it is also called as ventilator associated pneumonia. Major causative pathogens include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) has also been found to be a major causative agent of nosocomial pneumonia in new borne. ?
According to this study, over the next five years the Pipeline Analysis of Hospital Acquired Pneumonia Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Pipeline Analysis of Hospital Acquired Pneumonia Drugs business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Pipeline Analysis of Hospital Acquired Pneumonia Drugs market by product type, application, key manufacturers and key regions and countries.
This study considers the Pipeline Analysis of Hospital Acquired Pneumonia Drugs value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Tedizolid Phosphate
Ceftolozane/Tazobactam
Ceftazidime/Avibactum
Amikacin Inhale
Plazomicin
Synflorix Vaccine
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Bacterial Pneumonia
Viral Pneumonia
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Achaogen
Aridis Pharmaceuticals
AstraZeneca
Cubist Pharmaceuticals
Meiji Seika Pharma
Merck
Sanofi
GlaxoSmithKline
Valneva
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Pipeline Analysis of Hospital Acquired Pneumonia Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Pipeline Analysis of Hospital Acquired Pneumonia Drugs market by identifying its various subsegments.
Focuses on the key global Pipeline Analysis of Hospital Acquired Pneumonia Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Pipeline Analysis of Hospital Acquired Pneumonia Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Pipeline Analysis of Hospital Acquired Pneumonia Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
